keyword
MENU ▼
Read by QxMD icon Read
search

Serous carcinoma

keyword
https://www.readbyqxmd.com/read/28822556/associations-between-residual-disease-and-survival-in-epithelial-ovarian-cancer-by-histologic-type
#1
Alexander Melamed, Beryl Manning-Geist, Amy J Bregar, Elisabeth J Diver, Annekathryn Goodman, Marcela G Del Carmen, John O Schorge, J Alejandro Rauh-Hain
OBJECTIVE: Surgical cytoreduction has been postulated to affect survival by increasing the efficacy of chemotherapy in ovarian cancer. We hypothesized that women with high-grade serous ovarian cancer, which usually responds to chemotherapy, would derive greater benefit from complete cytoreduction than those with histologic subtypes that are less responsive to chemotherapy, such as mucinous and clear cell carcinoma. METHODS: We conducted a retrospective cohort study of patients who underwent primary cytoreductive surgery and adjuvant chemotherapy for stage IIIC or IV epithelial ovarian cancer from 2011 to 2013 using data from the National Cancer Database...
August 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28822373/masquerading-as-sigmoid-adenocarcinoma-a-unique-presentation-of-high-grade-serous-carcinoma-arising-from-endometriosis
#2
Wali R Johnson, Clark D Kensinger, Megan A Desai, Alexander T Hawkins
No abstract text is available yet for this article.
August 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28819560/a-novel-peptide-blocking-cancer-cell-invasion-by-structure-based-drug-design
#3
Yuki Yamada, Seiji Kanayama, Fuminori Ito, Noriyuki Kurita, Hiroshi Kobayashi
The receptor for the urokinase-type plasminogen activator (uPA), uPAR, facilitates tumor cell invasion and metastasis by focusing on several ligands, including uPA, integrins and vitronectin. With computational prediction algorithms and structure-based drug design, we identified peptides containing the Gly-Lys-Gly-Glu-Gly-Glu-Gly-Lys-Gly sequence (peptide H1), which strongly interacts with uPAR. The aim of the present study was to investigate the effect of allosteric inhibition at the uPAR interface using a novel synthetic peptide and its function on ovarian cancer cell invasion...
September 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28816970/skin-metastases-in-epithelial-ovarian-and-fallopian-tube-carcinoma
#4
Isao Otsuka, Takuto Matsuura
This study aimed to investigate the clinical features and outcomes of skin metastasis in ovarian and fallopian tube carcinomas.We studied patients with epithelial ovarian or fallopian tube carcinoma who developed skin metastasis from 2001 through 2012, and were also treated with chemotherapy and/or surgery.Skin metastases were classified as umbilical metastasis (Sister Joseph nodule [SJN]) and nonumbilical metastasis. Patients who developed skin metastases at paracentesis sites were excluded.Of the 206 patients treated, 12 (5...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28816710/establishment-of-primary-cell-culture-from-ascitic-fluid-and-solid-tumor-obtained-from-epithelial-ovarian-carcinoma-patients
#5
Rajarshi Kar, Diwesh Chawla, Bindiya Gupta, Mohit Mehndiratta, Neelam Wadhwa, Rachna Agarwal
OBJECTIVE: Ovarian cancer is the seventh leading cause of cancer death worldwide. This is mainly due to late diagnosis and high rate of relapse and resistance following chemotherapy. In the present study, we describe simple and cost-effective method to establish primary culture from ascitic fluid and solid tumor obtained from epithelial ovarian carcinoma patient, which may provide a better tool for in vitro testing of drug sensitivity and designing individualized treatment protocol. METHODS: Complete Dulbecco modified Eagle medium (DMEM) was prepared by supplementing DMEM with 10% fetal bovine serum and antibiotics (ciprofloxacin and amphotericin B)...
August 16, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28816557/cd44-as-a-cancer-stem-cell-marker-and-its-prognostic-value-in-patients-with-ovarian-carcinoma
#6
Alena Bartakova, Kveta Michalova, Jiri Presl, Pavel Vlasak, Jan Kostun, Jiri Bouda
The aim of our study was to clarify whether the CD44 adhesion molecule as a cancer stem cell marker could also serve as a prognostic factor in patients with epithelial ovarian cancer (EOC). A retrospective study was performed on 87 patients with histologically verified EOC. Specimens of both primary tumour and implantation metastases were tested from 48 of them. CD44 expression was detected by immunohistochemistry. We looked for the cut-off levels of CD44 expression using the Cox regression model. We confirmed statistically significant prognostic factors for overall survival (OS) and disease-free interval (DFI) to be: stage of the disease, postoperative residual tumour and papillary serous histological type...
August 17, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28816359/chrysin-attenuates-progression-of-ovarian-cancer-cells-by-regulating-signaling-cascades-and-mitochondrial-dysfunction
#7
Whasun Lim, Soomin Ryu, Fuller W Bazer, Sung-Man Kim, Gwonhwa Song
Chrysin is mainly found in passion flowers, honey, and propolis acts as a potential therapeutic and preventive agent to inhibit proliferation and invasion of various human cancer cells. Although chrysin has anti-carcinogenic effects in several cancers, little is known about its functional roles in ovarian cancer which shows poor prognosis and chemoresistance to traditional therapeutic agents. In the present study, we investigated functional roles of chrysin in progression of ovarian cancer cells using ES2 and OV90 (clear cell and serous carcinoma, respectively) cell lines...
August 17, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/28811894/the-conceptual-advances-of-carcinogenic-sequence-model-in-high-grade-serous-ovarian-cancer
#8
Hiroshi Kobayashi, Kana Iwai, Emiko Niiro, Sachiko Morioka, Yuki Yamada, Kenji Ogawa, Naoki Kawahara
The present review focuses on the current status of molecular pathology in high-grade serous cancer (HGSC) and preneoplastic conditions. This article reviews the English-language literature on HGSC, precursor, fallopian tubal epithelium, secretory cells, ciliated cells, secretory cell expansion, secretory cell outgrowth (SCOUT), p53 signature, serous tubal intraepithelial carcinoma (STIC), DNA damage and immunohistochemistry in an effort to identify the precursor-carcinoma sequence in HGSC. The majority of HGSC originates from the fimbriated end of the fallopian tube secretory epithelial cells, while the small part of this disease may develop from ovarian cortical inclusion cyst (CIC)...
September 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28810294/-morphologic-features-of-fallopian-tubal-epithelium-in-pelvic-high-grade-serous-carcinoma
#9
R J Zhao, Y Y Wang, Z Li, K Y Wu, L F Kong, W X Zheng
Objective: To study the pathologic features of fallopian tubal epithelium in patients with pelvic high-grade serous carcinoma (HGSC), to investigate its role in pelvic serous carcinogenesis and to reclassify the primary site of HGSC based on recently proposed criteria. Methods: The fallopian tubes in 58 cases of pelvic HGSC (54 cases of ovarian primary, 3 cases of tubal primary, 1 case of peritoneum) and 25 cases of pelvic non-HGSC (5 cases of ovarian low-grade serous cancer, 9 cases of endometrioid cancer, and 11 cases of clear cell ovary carcinoma) were collected from June 2015 to December 2016, and serially examined under light microscope (SEE-FIM protocol)...
August 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28807367/an-evaluation-of-progression-free-survival-and-overall-survival-of-ovarian-cancer-patients-with-clear-cell-carcinoma-versus-serous-carcinoma-treated-with-platinum-therapy-an-nrg-oncology-gynecologic-oncology-group-experience
#10
Kate E Oliver, William E Brady, Michael Birrer, David M Gershenson, Gini Fleming, Larry J Copeland, Krishnansu Tewari, Peter A Argenta, Robert S Mannel, Angeles Alvarez Secord, Jean-Marie Stephan, David G Mutch, Frederick B Stehman, Franco M Muggia, Peter G Rose, Deborah K Armstrong, Michael A Bookman, Robert A Burger, John H Farley
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). RESULTS: There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further...
August 11, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28804784/birinapant-sensitizes-platinum-resistant-carcinomas-with-high-levels-of-ciap-to-carboplatin-therapy
#11
V La, R Fujikawa, D M Janzen, M Nunez, L Bainvoll, L Hwang, K Faull, G Lawson, S Memarzadeh
Platinum drugs are the frontline therapy in many carcinomas, including high-grade serous ovarian cancers. Clinically, high-grade serous carcinomas have an apparent complete response to carboplatin, but tumors invariably recur and response to platinum drugs diminishes over time. Standard of care prohibits re-administration of platinum drugs to these patients who are labeled as having platinum-resistant disease. In this stage patients are treated with non-platinum agents and outcomes are often poor. In vivo and in vitro data presented here demonstrate that this clinical dogma should be challenged...
2017: NPJ Precis Oncol
https://www.readbyqxmd.com/read/28800941/survival-and-safety-associated-with-aggressive-surgery-for-stage-iii-iv-epithelial-ovarian-cancer-a-single-institution-observation-study
#12
Shinichi Tate, Kazuyoshi Kato, Kyoko Nishikimi, Ayumu Matsuoka, Makio Shozu
OBJECTIVE: We evaluated the efficacy and safety of aggressive surgery for advanced ovarian cancer at a non-high-volume center. MATERIALS AND METHODS: We evaluated consecutive patients with stage III/IV ovarian, fallopian, and peritoneal cancer undergoing elective aggressive surgery from January 2008 to December 2012, which encompassed the first 5years after implementing an aggressive surgery protocol. After receiving appropriate training for 9months, a gynecological surgical team began performing multi-visceral resections...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800940/neoadjuvant-chemotherapy-and-chemotherapy-cycle-number-a-national-multicentre-study
#13
Alon D Altman, Jacob McGee, Taymaa May, Kelly Lane, Lin Lu, Wei Xu, Prafull Ghatage, Barry Rosen
OBJECTIVES: Six cycles of consolidation chemotherapy have become the standard for ovarian cancer treatment regimen following primary cytoreduction, yet with neoadjuvant chemotherapy (NAC), only 3 consolidation cycles are used. This study examines the effects of number of chemotherapy cycles in women with ovarian cancer that are being treated with neoadjuvant chemotherapy. In addition, we examined the effect of number of cycles on survival on consolidation and total chemotherapy. METHODS: All patients with stage IIIC and IV high grade serous carcinoma (HGSC) were identified at 4 major Canadian cancer centers treated with NAC...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800130/mir-130a-upregulates-mtor-pathway-by-targeting-tsc1-and-is-transactivated-by-nf-%C3%AE%C2%BAb-in-high-grade-serous-ovarian-carcinoma
#14
Yuqiong Wang, Xiyu Zhang, Wei Tang, Zhenghong Lin, Limei Xu, Ruifen Dong, Yinuo Li, Jieyin Li, Zaixin Zhang, Xiangzhi Li, Ling Zhao, Jian-Jun Wei, Changshun Shao, Beihua Kong, Zhaojian Liu
Activation of mammalian target of rapamycin (mTOR) signaling pathway is associated with poor prognosis of epithelial ovarian cancer. The TSC1-TSC2 complex is a critical negative regulator of mTOR signaling. Here, we demonstrated that TSC1 was frequently downregulated in high-grade serous ovarian carcinoma (HGSOC) and low TSC1 expression level is associated with advanced tumor stage. We next identified miR-130a to be a negative regulator of TSC1 by targeting its 3'UTR. miR-130a was overexpressed in HGSOC and could drive proliferation and invasion/metastasis of ovarian cancer cells...
August 11, 2017: Cell Death and Differentiation
https://www.readbyqxmd.com/read/28800010/cell-polarity-reversal-distinguishes-true-micropapillary-growth-from-retraction-artifact-in-invasive-urothelial-carcinoma
#15
Yiang Hui, Kara A Lombardo, M Ruhul Quddus, Andres Matoso
Focal micropapillary features in invasive urothelial carcinoma is sometimes difficult to distinguish from retraction artifact morphologically. Cell polarity reversal has been demonstrated in micropapillary tumors by epithelial membrane antigen (EMA) immunostaining. We have previously described the use of E-cadherin as a cell polarity marker in ovarian micropapillary serous borderline tumors. The aim of this study was to evaluate the utility of immunohistochemistry for EMA and E-cadherin in differentiating micropapillary urothelial carcinoma from retraction artifact...
August 9, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28795841/serous-carcinoma-mimicking-primary-urothelial-carcinoma-on-clinical-evaluation-and-pathology-a-potential-diagnostic-pitfall
#16
Leili Mirsadraei, Alexey Hodkoff, Karra Jones, Ahmed Shabaik, A Karim Kader, Cheryl C Saenz, Rodolfo Montironi, David E Tacha, Oluwole Fadare, Donna E Hansel
CONTEXT: - Serous carcinoma of the gynecologic tract often involves the external bladder wall and can occasionally mimic primary urothelial carcinoma of the bladder. OBJECTIVE: - To define the spectrum of morphologic and immunohistochemical features that characterize serous carcinoma involving the bladder wall and its distinction from urothelial carcinoma. DESIGN: - We reviewed all cases of serous carcinoma secondarily involving the bladder wall from the University of California San Diego and Polytechnic Institute for histopathologic and immunohistochemical features...
August 10, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28781807/amplification-of-the-nsd3-brd4-chd8-pathway-in-pelvic-high-grade-serous-carcinomas-of-tubo-ovarian-and-endometrial-origin
#17
Derek H Jones, Douglas I Lin
Identification of novel therapeutics in pelvic high-grade serous carcinoma (HGSC) has been hampered by a paucity of actionable point mutations in target genes. The aim of the present study was to investigate the extent of amplification of the therapeutically targetable NSD3-CHD8-BRD4 pathway in pelvic HGSC, and to determine whether amplification is associated with worse prognosis. The Cancer Genome Atlas (TCGA) ovarian and endometrial cancer cohorts were retrospectively analyzed via online data-mining tools to test the association of NSD3, CHD8 and BRD4 genomic alterations with survival of pelvic HGSC patients...
August 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28778086/connective-tissue-growth-factor-mediates-tgf-%C3%AE-1-induced-low-grade-serous-ovarian-tumor-cell-apoptosis
#18
Jung-Chien Cheng, Hsun-Ming Chang, Peter C K Leung
Ovarian low-grade serous carcinoma (LGSC) is a rare disease and is now considered to be a distinct entity from high-grade serous carcinoma (HGSC), which is the most common and malignant form of epithelial ovarian cancer. Connective tissue growth factor (CTGF) is a secreted matricellular protein that has been shown to modulate many biological functions by interacting with multiple molecules in the microenvironment. Increasing evidence indicates that aberrant expression of CTGF is associated with cancer development and progression...
July 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28768570/primary-cytoreductive-surgery-and-adjuvant-hormonal-monotherapy-in-women-with-advanced-low-grade-serous-ovarian-carcinoma-reducing-overtreatment-without-compromising-survival
#19
Amanda N Fader, Jennifer Bergstrom, Amelia Jernigan, Edward J Tanner, Kara Long Roche, Rebecca L Stone, Kimberly L Levinson, Stephanie Ricci, Stephanie Wethingon, Tian-Li Wang, Ie-Ming Shih, Bin Yang, Gloria Zhang, Deborah K Armstrong, Stephanie Gaillard, Chad Michener, Robert DeBernardo, Peter G Rose
OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS: A retrospective study was performed at two academic cancer centers...
July 30, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28767420/ccne1-expression-in-high-grade-serous-carcinoma-does-not-correlate-with-chemoresistance
#20
Stav Sapoznik, Sarit Aviel-Ronen, Keren Bahar-Shany, Oranit Zadok, Keren Levanon
Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplification, occurring in ~20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition. The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance...
July 15, 2017: Oncotarget
keyword
keyword
95673
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"